D
Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
D
Sell
10/17/2024Upgraded
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D- from E+ on 10/17/2024 due to an increase in the volatility index, total return index and valuation index.
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D- from E+ on 10/17/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
5/14/2024Downgrade
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E+ from D on 5/14/2024 due to a significant decline in the growth index, efficiency index and solvency index. EBIT declined 6,414.89% from $1.93M to -$122.13M, earnings per share declined from $0.0694 to -$1.7507, and net income declined 2,610.95% from $4.73M to -$118.79M.
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E+ from D on 5/14/2024 due to a significant decline in the growth index, efficiency index and solvency index. EBIT declined 6,414.89% from $1.93M to -$122.13M, earnings per share declined from $0.0694 to -$1.7507, and net income declined 2,610.95% from $4.73M to -$118.79M.
D
Sell
11/10/2023Upgraded
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D from D- on 11/10/2023 due to a significant increase in the efficiency index and volatility index. Total capital increased 8.05% from $391.65M to $423.17M.
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D from D- on 11/10/2023 due to a significant increase in the efficiency index and volatility index. Total capital increased 8.05% from $391.65M to $423.17M.
D
Sell
9/11/2023Upgraded
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D- from E+ on 9/11/2023 due to a large increase in the growth index and valuation index. Earnings per share increased from $0.02 to $0.31, EBIT increased 1,083.97% from -$2.05M to $20.2M, and operating cash flow increased 269.74% from -$5.07M to $8.61M.
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D- from E+ on 9/11/2023 due to a large increase in the growth index and valuation index. Earnings per share increased from $0.02 to $0.31, EBIT increased 1,083.97% from -$2.05M to $20.2M, and operating cash flow increased 269.74% from -$5.07M to $8.61M.
E
Sell
6/12/2023Downgrade
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
D
Sell
3/29/2023Upgraded
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index and valuation index.
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index and valuation index.
E
Sell
3/14/2023Downgrade
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D from E+ on 2/9/2023 due to an increase in the valuation index.
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D from E+ on 2/9/2023 due to an increase in the valuation index.
E
Sell
2/8/2023Downgrade
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, efficiency index and valuation index. Total capital declined 24.56% from $199.86M to $150.79M.
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index, efficiency index and valuation index. Total capital declined 24.56% from $199.86M to $150.79M.
D
Sell
8/30/2022Upgraded
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D from D- on 8/30/2022 due to a substantial increase in the total return index.
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D from D- on 8/30/2022 due to a substantial increase in the total return index.
D
Sell
8/15/2022Downgrade
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to D- from D on 8/15/2022 due to a noticeable decline in the efficiency index, solvency index and growth index. Total capital declined 19.45% from $248.14M to $199.86M, the quick ratio declined from 9.21 to 7.61, and operating cash flow declined 14.34% from -$40.63M to -$46.46M.
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to D- from D on 8/15/2022 due to a noticeable decline in the efficiency index, solvency index and growth index. Total capital declined 19.45% from $248.14M to $199.86M, the quick ratio declined from 9.21 to 7.61, and operating cash flow declined 14.34% from -$40.63M to -$46.46M.
D
Sell
7/26/2022Upgraded
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D from D- on 7/26/2022 due to an increase in the volatility index and total return index.
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D from D- on 7/26/2022 due to an increase in the volatility index and total return index.
D
Sell
6/28/2022Upgraded
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D- from E- on 6/28/2022 due to an increase in the volatility index.
Amylyx Pharmaceuticals, Inc. (AMLX) was upgraded to D- from E- on 6/28/2022 due to an increase in the volatility index.
E
Sell
5/13/2022None
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E- from U on 05/13/2022.
Amylyx Pharmaceuticals, Inc. (AMLX) was downgraded to E- from U on 05/13/2022.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
